...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Agoracom News Flash above

This stock whose name cannot be mentioned is very interesting and the warrants are great value. They have added to their drug products line, have HC approval for one and await FDA approval for it. Revenues are about to move up dramatically. I have been into it for a while and suggest you take a look. Another worthwhile one in the same line is MDP.

1
Dec 17, 2020 08:01AM
Share
New Message
Please login to post a reply